Skip to main content

deutivacaftor; tezacaftor; vanzacaftor

Generic: DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM·Brand: ALYFTREK

deutivacaftor; tezacaftor; vanzacaftor: developed by 1 company · 1 FDA decision.

deutivacaftor; tezacaftor; vanzacaftor evidence translation

What we can confirm

What it means

Source-backed records connect deutivacaftor; tezacaftor; vanzacaftor to VRTX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could deutivacaftor; tezacaftor; vanzacaftor → VRTX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (2)
CompanyPhase
VERTEX PHARMACEUTICALS INC / MA (VRTX)Approved
VERTEX PHARMACEUTICALS INC / MA (VRTX)Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 5 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ]. If the patient's genotype is unknown, an FDA-cleared C(VRTX)FDA ↗
NDA218730Type 1 - New Molecular EntityOrphan DrugPriorityOralTablet

Frequently asked questions

Who is developing deutivacaftor; tezacaftor; vanzacaftor?

deutivacaftor; tezacaftor; vanzacaftor is being developed by VERTEX PHARMACEUTICALS INC / MA.

What is deutivacaftor; tezacaftor; vanzacaftor's latest FDA decision?

The most recent tracked FDA decision for deutivacaftor; tezacaftor; vanzacaftor is Approval for 1 INDICATIONS AND USAGE ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 5 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ]. If the patient's genotype is unknown, an FDA-cleared C, dated December 20, 2024.